We are developing PIKA-based vaccines to prevent or treat infectious disease, including COVID 19, hepatitis B, rabies and flu. YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. YS Biopharma operates in China, Singapore, the United States, the United Arab Emirates and the Philippines with over 800 employees and led by a management team that combines rich local expertise and global vision in the vaccine and pharmaceutical industry. When delivered with relevant protein-based molecules, PIKA technology is offering a promising platform for the development of a wide variety of novel biotherapeutics as new generation of antiviral vaccines, antiviral therapeutics and anticancer therapeutics.
Beijing, China
Founded in 2002
501-1000 Employees
Medium-Sized
Working industry
Other
Type of company
Manufacturer
Locations
1 Headquarter
Specialised areas
Biopharma, Biotechnology
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
China
Overall risk estimation:
High
The ESG Data of countries are based on public sources
Environment
E
Grade (A-E)
View details
Social
C
Grade (A-E)
View details
Governance
E
Grade (A-E)
View details
Yisheng Biopharma operates in 1 country around the world
Get an overview of the locations of Yisheng Biopharma
Location
Country
State
City
Headquarter
China
Beijing
Beijing
Some frequent questions that have been asked about Yisheng Biopharma
Where is Yisheng Biopharma located?
The company headquarter of Yisheng Biopharma is located in Beijing, Beijing, China. It's worth noting, that the company may have more locations
How many employees does Yisheng Biopharma approximately have?
As of the latest available information Yisheng Biopharma has around 501-1000 employees worldwide.
When was Yisheng Biopharma founded?
Yisheng Biopharma was founded in 2002
In which industries does Yisheng Biopharma mainly work?
The company Yisheng Biopharma has it's main focus in the industries of Other
What is the current company status of Yisheng Biopharma?
Based on the founding year and the amount of employees the company Yisheng Biopharma seems to be a Medium-Sized at the current state. Note that over time that status can change
Check out some interesting alternative companies to Yisheng Biopharma
Yapan Bio
Makkajipalli, India
11-50 Employees
2019
We provide services to develop and manufacture high-quality Vaccines and Biologics/Bio-therapeutic, to support global biotechnology and biopharma companies, meeting customer satisfaction in compliance with Quality, Regulatory and GMP expectations. Yapan Bio is a Contract Development and Manufacturing Organization (CDMO) serving the needs of the biotechnology industry, globally. Yapan Bio provides robust process development, appropriate scale-up and compliant GMP manufacturing of Vaccines and Biologics/Bio-therapeutics for human clinical studies across the world. Yapan Bio has established state-of-the-art Process Development and GMP facilities for vaccines and biologics, including higher Bio-Safety levels (up to BSL-2+). To provide customized high-quality integrated services to our partners. Yapan Bio was founded by two industry veterans, Atin Tomar and Nirav Desai, with a proven leadership track record in both technical and leadership roles in the biotechnology industry, globally. Yapan Bio’s focus and expertise is in the development and manufacturing of next generation and highly complex molecules/products (recombinant vaccines, viral and non-viral vector-based products, Gene Therapy, monoclonal antibodies etc.). Optimization and scale-up for high product titer, stability and consistent manufacturing output.
VEROVACCiNES GmbH
Halle (Saale), Germany
1-10 Employees
2017
After validating the novel technology platform (Proof of Concept in several vaccine programs), we are pursuing development of our product pipeline and scaling up manufacturing. We discover and develop innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate modern recombinant combination vaccines.
BunyaVax
Lelystad, Netherlands
1-10 Employees
2017
BunyaVax exploits proprietary technology to develop safe and efficacious vaccines against neglected diseases of animals and humans. BunyaVax has developed proprietary technologies to attenuate bunyaviruses and uses these technologies to develop live attenuated vaccines that optimally combine efficacy with safety. BunyaVax prioritizes viral pathogens that affect animal and human health in developing countries and is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) and leading human and animal health pharma. BunyaVax prioritizes viral diseases caused by bunyaviruses and other insect- and tick-borne viruses, including those listed on the WHO Blueprint list. Apart from vaccines, BunyaVax is using proprietary technologies to develop innovative diagnostics.
United Biomedical,Inc
Town of Smithtown, United States
11-50 Employees
1985
We are a multinational biopharmaceutical organization dedicated to the development of diagnostics and immunotherapeutics for the improvement of global health. Founded in 1985, we are a private, closely held company passionate about delivering science-driven innovation with platform capabilities. Our companies cover novel drug discovery and development, CDMO services, and manufacturing capabilities across vaccines, protein and antibodies, specialty injectables and small molecules. Our product pipeline across these companies include the prevention and treatment of indications in neurology, immunology and infectious diseases for both animal and human health. Delivering specialty injectables/ proteins and world-class CMO services.
Generon (Shanghai) Corporation
Shanghai, China
51-100 Employees
2004
Evive Biotech, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, EU, Singapore, and China. As one of the top biopharmaceutical companies to develop innovative therapies from China for the world, Evive adopts a holistic approach for drug development, combining exceptional preclinical and clinical research capabilities with our world-class in-house manufacture and regulatory expertise as well as extensive global drug development experience. Become a global commercial-stage biopharmaceutical company dedicated to the development of innovative medicines for patients with unmet medical needs in the areas of oncology, inflammatory or metabolic diseases. Build strong global drug development and commercialization capabilities, including cutting-edge innovative R&D centers, strong clinical development teams, well-recognized regulatory affairs experts, large-molecule manufacturing facilities meeting international GMP standards, and specialized commercial teams. Generate a broad product pipeline with worldwide commercialization of F-627 as a novel treatment for chemotherapy-induced neutropenia, one indication of F-652 submitted for market approval in China, two indications in late-stage clinical development, and multiple product candidates in early clinical or pre-clinical development stages that have been developed with first-in-class or best-in-class potential by in-house R&D teams. Building a Broad Product Pipeline with Worldwide Commercialization.
Saiba Animal Health AG
Schlieren, Switzerland
1-10 Employees
2013
Saiba Animal Health AG was founded as a spin-off company from the University of Zürich in 2013 by Patrik Paulus, Gabriela Senti, Thomas Kündig and Martin Bachmann. In 2014 Saiba Animal Health received a R&D project grant from the Swiss Commission for Technology and Innovation to advance the HypoCat vaccine project and later that year entered into a Commercialization, manufacture, and distribution agreement with Benchmark Holdings PLC. Saiba Animal Health has developed a novel and innovative vaccine platform that is based on non-infectious virus-like particles in order to treat chronic inflammatory diseases, cancer and allergy in pets. Our team of innovative scientists, veterinarians and businessmen has pioneered and developed expertise and proprietary rights relating to a unique virus-like particle (VLP) vaccine nanotechnology platform. Saiba Animal Health was founded as a spin-off company from the University Zurich in 2013.